Home page > Publications > MGHI papers
MGHI papers
Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol and Vinblastine-Based Metronomic Chemotherapy: A Bench to Bedside Study
Eddy Pasquier, Nicolas André, Janine Street, Anuradha Chougulee, Bharat Rekhif, Jaya Ghoshe, Deepa S.J. Philipe, Marie Meurer, Karen L. MacKenzie, Maria Kavallaris Shripad D. Banavali from the INSERM UMR 911, Centre de Recherche en Oncologie biologique et Oncopharmacologie, Aix-Marseille University, Metronomics, Global Health Initiative, the Service (...)
Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma
We have just published a preclinical study entitled : Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma that reports on the use of two repositionned drugs to treat low grade glioma. The authors of this study (Sandy Mercurio, Laetitia Padovani, Carole Colin, Manon Carré, Aurélie (...)
Has the time come for metronomics in low-income and middle-income countries?
In the May issue of the Lancet Oncology, We have published a "personnal view" paper about the potential use of Metronomics in low and middle income countries. We hope this publications will help us raise awareness about the potential of the approach and find new partners, supporters and ambassadors. ABSTRACT In 2008, 72% of cancer deaths occurred in (...)
Herbal Medicine Offers Great Potential in Support of Metronomic Cancer Therapy
Clara Bik-San Lau, Chun-Kwok Wong and Ping-Chung Leung from Partner State Key Laboratory of Phytochemistry and Plant Resources in West China, The Chinese University of Hong Kong, , Institute of Chinese Medicine, The Chinese University of Hong Kong and Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Konghve just published in (...)
Highlights from the 1st Latin American meeting on metronomic chemotherapy and drug repositioning in oncology
The report from the 1st Latin American meeting on metronomic chemotherapy and drug repositioning in oncology which took place on the 27–28th of May 2016 in Rosario, Argentina, and organized by Pr Graciela Scharovsky has just been published in Ecancermedicalsciences. The article entitled "Highlights from the 1st Latin American meeting on metronomic (...)
Investment in cancer studies in countries of low and middle income
A proposal to fund clinical studies in low income countries has just been proposed by MGHI and accepted by the Lancet. This letter to the editor written by 3 MGHI members (Eddy Pasquier, Brendan Guercio and Nicolas André, is entitled "Investment in cancer studies in countries of low and middle income". You can read it in the attached file or on the (...)
Irinotecan dose schedule for the treatment of Ewing sarcoma—protracted/metronomic schedule—wording
This is a comment by Nicolas ANDRE from the Department of Pediatric Hematology and Oncology, Hôpital de La Timone, AP-HM, the UMR Inserm 1068, CNRS UMR 7258, AixMarseille Université U105, Marseille Cancer Research Center (CRCM) and Metronomics Global Health Initiative,Marseille, France published in Pediatric Blood and Cancer The special report from (...)
Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting
We are delighted to provide the report form the 4th metronomic meeting which took place’ in Milano last June. The report entitled Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting has been written by Gauthier Bouche from the Anticancer Fund, with several members of the Metronomics Global Health Initiative as coauthors. The report has (...)
Maintenance chemotherapy in children with ALL exerts metronomic-like thrombospondin-1 associated anti-endothelial effect
Our lastest article entitled Maintenance chemotherapy in children with ALL exerts metronomic-like thrombospondin-1 associated anti-endothelial effect has just been published in Oncotarget. This study has been performed the Service d’Hématologie et Oncologie Pédiatrique, Centre Hospitalo-Universitaire Timone Enfants and the Laboratoire d’Hématologie, (...)
METRO-PD1: Phase 1 study of nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing/refractory solid tumors
Our recent phase 1 trial exploring the combination of Nivolumab and metronomic chemotherapy entitled: METRO-PD1: Phase 1 study of nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing/refractory solid tumors has just been published in the European Journal of Cancer by Nicolas André, Marie Cécile Le Deley, (...)
